Humacyte, Inc.
HUMA
$1.26
-$0.05-3.82%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 2.36% | 23.58% | 51.88% | 23.07% | 34.92% |
| Gross Profit | -2.36% | -23.58% | -51.88% | -23.07% | -34.92% |
| SG&A Expenses | 23.83% | 20.38% | 86.32% | 1.53% | 2.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.28% | 22.79% | 24.87% | 18.06% | 25.94% |
| Operating Income | -7.28% | -22.79% | -24.87% | -18.06% | -25.94% |
| Income Before Tax | 16.59% | -50.81% | -149.55% | 13.72% | -574.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.59% | -50.81% | -149.55% | 13.72% | -574.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.59% | -50.81% | -149.55% | 13.72% | -574.89% |
| EBIT | -7.28% | -22.79% | -24.87% | -18.06% | -25.94% |
| EBITDA | -7.93% | -24.70% | -28.09% | -21.27% | -30.38% |
| EPS Basic | 31.94% | -30.64% | -116.43% | 17.68% | -571.19% |
| Normalized Basic EPS | 19.12% | -7.13% | -12.79% | -14.29% | -28.05% |
| EPS Diluted | 31.94% | -30.64% | -116.43% | 17.68% | -571.19% |
| Normalized Diluted EPS | 19.12% | -7.13% | -12.79% | -14.29% | -28.05% |
| Average Basic Shares Outstanding | 22.56% | 15.43% | 15.30% | 4.83% | 0.43% |
| Average Diluted Shares Outstanding | 22.56% | 15.43% | 15.30% | 4.83% | 0.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |